CDK Inhibition in Lung Cancer Alters Epithelial–Mesenchymal Transition, Autophagy, and Metabolism
Current Cancer Drug Targets, 2026
Publications
17
Peer-reviewed
Citations
124
Total across all work
h-index
7
Sustained impact
Trajectory
Citation growth over time
Research Articles
Latest first · click any title to open the paper.
Current Cancer Drug Targets, 2026
We use AutoGluon to predict drug-drug interactions and show that automated model search with molecular fingerprints can match handcrafted pipelines while staying simple to reproduce.
Toxicology Mechanisms and Methods, 2026
PLoS ONE, 2026
Cross-sectional survey of public perceptions of AI-assisted cancer care in Abu Dhabi. Reports attitudes, trust gaps, and the demographic patterns that shape adoption.
Supportive Care in Cancer, 2026
Review of thymoquinone as a targeted cancer therapy. Walks through molecular mechanisms and the clinical prospects that depend on solving the formulation problem.
International Journal of Molecular Sciences, 2025
First-author review of inhalable nanoparticle-based drug delivery for non-small cell lung cancer. Maps the design choices that improve targeting and the translational gaps still in the way.
Saudi Pharmaceutical Journal, 2025
A methodological audit of tumour-progression ML papers, showing how weak validation choices inflate apparent performance and what an honest benchmark would look like in oncology.
Computers in Biology and Medicine, 2025
Synergistic modulation of ER stress combined with insulin potentiation therapy for enhanced cancer treatment. Reports a combination strategy validated across cancer cell lines.
Cell Therapy & Engineering Connect, 2025
First-author review of large language models in drug delivery. Covers what LLM-powered tools currently do for formulation and what would have to be true before they replace manual triage.
Journal of Pharmaceutical Sciences, 2025
First-author work on spatially resolved airway niches in asthma, mapping epithelial-immune microenvironments that shape disease heterogeneity.
Expert Review of Respiratory Medicine, 2025
Discovery of small ERK5 inhibitors through structure-based virtual screening, biological evaluation, and MD simulations. Reports candidates that survived in-vitro validation.
Molecules, 2025
A landscape review of nanomedicine platforms used in smart chemotherapy. Maps how surface chemistry, stimulus-responsive carriers, and combination approaches are being used to lower off-target toxicity.
Pharmaceuticals, 2024
First-author work on a theophylline controlled-release matrix system combining poloxamer 407, stearyl alcohol, and HPMC. Reports a formulation that survives multi-batch dissolution-profile testing.
Polymers, 2024
First-author follow-up on theophylline controlled-release tablets. Examines how hydration forms and polymer grades change release kinetics and how to control for them in formulation work.
Pharmaceuticals, 2024
We show how excipient choice changes the immediate-release profile of generic metformin HCl tablets, with practical implications for formulation re-validation.
Pharmaceuticals, 2023
Effect of enteric-coating film on the delayed release of pantoprazole gastro-resistant generic tablets. Walks through the formulation choices that survived re-validation across batches.
F1000Research, 2023
GC-MS characterisation of UAE-grown rosemary essential oil. Reports the major-constituent profile and contrasts it with regional sources.
Journal of Essential Oil Bearing Plants, 2022
Network
Built from OpenAlex authorships across every indexed publication. Node size and edge weight scale with the number of shared papers.